Smartleaf Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Smartleaf Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-116	Closed	-$5.45K	–	3070
2025 Q2	$5.45K	Sell	116 -368	-76%	-$16.4K	﹤0.01%	2019
2025 Q1	$22.9K	Buy	484 +96	+25%	+$4.42K	﹤0.01%	1547
2024 Q4	$14.1K	Buy	388 +135	+53%	+$4.72K	﹤0.01%	1845
2024 Q3	$8.17K	Buy	253 +133	+111%	+$4.97K	﹤0.01%	1882
2024 Q2	$4.5K	Buy	+120	New	+$5.05K	﹤0.01%	1853

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Smartleaf Asset Management's SWTX Position: Q3 2025 in Review

Smartleaf Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 116 shares — an estimated $5.45K sold.

Smartleaf Asset Management first reported a position in SWTX in Q2 2024 and held it in 5 quarters. The position peaked at $22.9K in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Smartleaf Asset Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Smartleaf Asset Management sold 116 SpringWorks Therapeutics shares in Q3 2025, an estimated $5.45K.
Smartleaf Asset Management first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 5 quarters.
Smartleaf Asset Management's SpringWorks Therapeutics position peaked at $22.9K in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Smartleaf Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.